Alpha-1 adrenoceptor blockade: potential new treatment for anal fissures. 2000

J Pitt, and M M Craggs, and M M Henry, and P B Boulos
University College London Medical School, United Kingdom.

OBJECTIVE Patients with chronic anal fissures are known to have high resting anal pressures that return to normal after successful surgical treatment. Internal anal sphincter activity is increased by sympathetic excitatory innervation via alpha adrenoceptors. The objective of this study was to determine the effect of alpha-1 adrenoceptor blockade on anal sphincter pressure in patients with and without chronic anal fissures. METHODS The effect on the anal canal pressure profile of a single oral 20 mg dose of indoramin, an alpha-1 adrenoceptor antagonist, on seven patients with chronic anal fissure and six healthy patients without a fissure was investigated. RESULTS Indoramin reduced anal resting pressures in those with anal fissure by a mean of 35.8 percent, from 106.9 +/- 22.15 cm H2O to 68.6 +/- 20.35 cm H2O, and in those without anal fissure by a mean of 39.9 percent, from 84.17 +/- 27.46 cm H2O to 52.17 +/- 24.78 cm H2O, after one hour. This pressure reduction persisted at three hours, and its magnitude is comparable to that obtained after internal sphincterotomy. The pressure reduction occurred over the whole length of the anal canal. CONCLUSIONS It is proposed that alpha-1 adrenoceptor antagonists could be a suitable treatment for chronic anal fissure and other painful conditions where reduction in anal pressure is warranted.

UI MeSH Term Description Entries
D007217 Indoramin An alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent. Wy-21901,Wy 21901,Wy21901
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D005401 Fissure in Ano A painful linear tear at the margin of the anus. It appears as a crack or slit in the mucous membrane of the anus and is very painful and difficult to heal. Anal Fissure,Anal Ulcer,Anal Ulcers,Fissure, Anal,Ulcer, Anal,Ulcers, Anal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J Pitt, and M M Craggs, and M M Henry, and P B Boulos
March 1998, British journal of urology,
J Pitt, and M M Craggs, and M M Henry, and P B Boulos
February 2005, Diseases of the colon and rectum,
J Pitt, and M M Craggs, and M M Henry, and P B Boulos
March 2000, Diseases of the colon and rectum,
J Pitt, and M M Craggs, and M M Henry, and P B Boulos
September 1951, La Semana medica,
J Pitt, and M M Craggs, and M M Henry, and P B Boulos
October 2017, Ugeskrift for laeger,
J Pitt, and M M Craggs, and M M Henry, and P B Boulos
May 1999, Prostate cancer and prostatic diseases,
J Pitt, and M M Craggs, and M M Henry, and P B Boulos
September 1990, Lancet (London, England),
J Pitt, and M M Craggs, and M M Henry, and P B Boulos
July 2008, Diseases of the colon and rectum,
J Pitt, and M M Craggs, and M M Henry, and P B Boulos
February 1992, Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti,
J Pitt, and M M Craggs, and M M Henry, and P B Boulos
June 1951, Lekarske listy,
Copied contents to your clipboard!